Business
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient interestTopline interim data readout expected in 1H2026 Phase 3 combination regimen continues under FDA Fast Track designation PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a
About this update from Briacell Therapeutics Corp
[{"type":"image","alt":"BriaCell Therapeutics Corp.","displaySize":"","headline":null,"caption":"BriaCell Therapeutics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VF.3uZP0Y9S.3O0ulWOxbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0f690ec91d7c396d79b761df6835fd7","width":300,"height":263}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment exceeding expectations with strong clinical site and patient interest","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline interim data readout expected in 1H2026 ","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 3 combination regimen continues under FDA Fast Track designation ","length":70,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":324,"olType":false},{"type":"text","content":"PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 clinical study has screened over 230 and enrolled over 160 patients. BriaCell anticipates reporting topline data as early as 1H2026.","length":437,"tagName":"p"},{"type":"text","content":"Interim data will be analyzed once 144 patient events (deaths) occur. Positive results from this pivotal study could support full approval and marketing authorization of Bria-IMT™ in patients with metastatic breast cancer.","length":222,"tagName":"p"},{"type":"text","content":"BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, plus an immune check point inhibitor versus physician’s choice in advanced metastatic breast cancer (Bria-ABC).","length":213,"tagName":"p"},{"type":"text","content":"“The pace of patient enrollment in our pivotal Phase 3 study has exceeded expectations underscoring the...